Volume 5, Issue 4, Page 11 (July 2010)
15 of 15
PREVIEW
FULL TEXT
FULL-TEXT PDF (94 KB)
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE
RIGHTS/PERMISSIONS
NEED REPRINTS?
BOOKMARK ARTICLE
ROME — Patients with systemic juvenile idiopathic arthritis who were treated with the interleukin 6–inhibitor drug tocilizumab produced strong responses in a randomized, multicenter, placebo-controlled trial.
From the annual European Congress of Rheumatology
PII: S1876-1143(10)70051-3
doi:10.1016/S1876-1143(10)70051-3
© 2010 Elsevier Inc. All rights reserved.
Copyright © 2012 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
PREVIEW